These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 25573098)

  • 81. ERCC1 expression as a prognostic marker in N2(+) nonsmall-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy.
    Hwang IG; Ahn MJ; Park BB; Ahn YC; Han J; Lee S; Kim J; Shim YM; Ahn JS; Park K
    Cancer; 2008 Sep; 113(6):1379-86. PubMed ID: 18623378
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Differential expression and prognostic value of ERCC1 and thymidylate synthase in resected gastric adenocarcinoma.
    Squires MH; Fisher SB; Fisher KE; Patel SH; Kooby DA; El-Rayes BF; Staley CA; Farris AB; Maithel SK
    Cancer; 2013 Sep; 119(17):3242-50. PubMed ID: 23719746
    [TBL] [Abstract][Full Text] [Related]  

  • 83. RRM1, TUBB3, TOP2A, CYP19A1, CYP2D6: Difference between mRNA and protein expression in predicting prognosis of breast cancer patients.
    Xu YC; Zhang FC; Li JJ; Dai JQ; Liu Q; Tang L; Ma Y; Xu Q; Lin XL; Fan HB; Wang HX
    Oncol Rep; 2015 Oct; 34(4):1883-94. PubMed ID: 26252353
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Impact of ERCC1 expression on treatment outcome in small-cell lung cancer patients treated with platinum-based chemotherapy.
    Sodja E; Knez L; Kern I; Ovčariček T; Sadikov A; Cufer T
    Eur J Cancer; 2012 Dec; 48(18):3378-85. PubMed ID: 22795264
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Immunohistochemistry evaluation of biomarker expression in non-small cell lung cancer (Pharmacogenoscan study).
    Toffart AC; Timsit JF; Couraud S; Merle P; Moro-Sibilot D; Perol M; Mastroianni B; Souquet PJ; Girard N; Jeannin G; Romand P; Chatellain P; Vesin A; Brambilla C; Brambilla E
    Lung Cancer; 2014 Feb; 83(2):182-8. PubMed ID: 24388706
    [TBL] [Abstract][Full Text] [Related]  

  • 86. The relationship of platinum resistance and ERCC1 protein expression in epithelial ovarian cancer.
    Steffensen KD; Waldstrøm M; Jakobsen A
    Int J Gynecol Cancer; 2009 Jul; 19(5):820-5. PubMed ID: 19574766
    [TBL] [Abstract][Full Text] [Related]  

  • 87. ERCC1 mRNA expression is associated with the clinical outcome of non-small cell lung cancer treated with platinum-based chemotherapy.
    Zhang H; Li J; Zhang Y; Sun M; Zhao P; Zhang G; Jin C; Sun L; He M; Wang B; Zhang X
    Genet Mol Res; 2014 Dec; 13(4):10215-22. PubMed ID: 25501233
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy.
    Bellmunt J; Paz-Ares L; Cuello M; Cecere FL; Albiol S; Guillem V; Gallardo E; Carles J; Mendez P; de la Cruz JJ; Taron M; Rosell R; Baselga J;
    Ann Oncol; 2007 Mar; 18(3):522-8. PubMed ID: 17229776
    [TBL] [Abstract][Full Text] [Related]  

  • 89. [Examination of ERCC1 expression in lung cancer patients treated with platinum-based chemotherapy].
    Moldvay J; Pápay J; Puskás R; Furák J; Losonczy G; Matolcsy A
    Magy Onkol; 2011 Jun; 55(2):105-9. PubMed ID: 21655476
    [TBL] [Abstract][Full Text] [Related]  

  • 90. ERCC1 and topoisomerase I expression in small cell lung cancer: prognostic and predictive implications.
    Sereno M; Cejas P; Moreno V; Belda-Iniesta C; López R; Nistal M; Feliu J; De Castro Carpeño J
    Int J Oncol; 2012 Jun; 40(6):2104-10. PubMed ID: 22344449
    [TBL] [Abstract][Full Text] [Related]  

  • 91. DNA repair gene polymorphisms and benefit from gefitinib in never-smokers with lung adenocarcinoma.
    Han JY; Yoon KA; Park JH; Lee YJ; Lee GK; Han JH; Yoon SJ; Yun T; Kim HT; Lee JS
    Cancer; 2011 Jul; 117(14):3201-8. PubMed ID: 21264830
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Excision repair cross complementing-1 and topoisomerase IIalpha gene expression in small-cell lung cancer patients treated with platinum and etoposide: a retrospective study.
    Ceppi P; Longo M; Volante M; Novello S; Cappia S; Bacillo E; Selvaggi G; Saviozzi S; Calogero R; Papotti M; Scagliotti GV
    J Thorac Oncol; 2008 Jun; 3(6):583-9. PubMed ID: 18520795
    [TBL] [Abstract][Full Text] [Related]  

  • 93. A phase 2 cooperative group adjuvant trial using a biomarker-based decision algorithm in patients with stage I non-small cell lung cancer (SWOG-0720, NCT00792701).
    Bepler G; Zinner RG; Moon J; Calhoun R; Kernstine K; Williams CC; Mack PC; Oliveira V; Zheng Z; Stella PJ; Redman MW; Gandara DR
    Cancer; 2014 Aug; 120(15):2343-51. PubMed ID: 24752945
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Blood mRNA expression of REV3L and TYMS as potential predictive biomarkers from platinum-based chemotherapy plus pemetrexed in non-small cell lung cancer patients.
    Agulló-Ortuño MT; García-Ruiz I; Díaz-García CV; Enguita AB; Pardo-Marqués V; Prieto-García E; Ponce S; Iglesias L; Zugazagoitia J; López-Martín JA; Paz-Ares L; Nuñez JA
    Cancer Chemother Pharmacol; 2020 Mar; 85(3):525-535. PubMed ID: 31832811
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Differential molecular markers of primary lung tumors and metastatic sites indicate different possible treatment selections in patients with metastatic lung adenocarcinoma.
    Deng LL; Deng HB; Lu CL; Gao G; Wang F; Yang Y
    Clin Transl Oncol; 2019 Feb; 21(2):197-205. PubMed ID: 29948972
    [TBL] [Abstract][Full Text] [Related]  

  • 96. ERCC1, RRM1 and TUBB3 mRNA expression on the tumor response and overall survival of non-small cell lung cancer treated with platinum-based chemotherapy.
    Qiao H; Huang X; Guo H; Liu Y; Yue C
    Pak J Med Sci; 2014; 30(6):1403-8. PubMed ID: 25674147
    [TBL] [Abstract][Full Text] [Related]  

  • 97. The expression of ERCC1, RRM1, and BRCA1 in breast cancer according to the immunohistochemical phenotypes.
    Kim D; Jung W; Koo JS
    J Korean Med Sci; 2011 Mar; 26(3):352-9. PubMed ID: 21394302
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Thymidylate synthase in situ protein expression and survival in stage I nonsmall-cell lung cancer.
    Zheng Z; Li X; Schell MJ; Chen T; Boulware D; Robinson L; Sommers E; Bepler G
    Cancer; 2008 Jun; 112(12):2765-73. PubMed ID: 18442042
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Cisplatin benefit is predicted by immunohistochemical analysis of DNA repair proteins in squamous cell carcinoma but not adenocarcinoma: theranostic modeling by NSCLC constituent histological subclasses.
    Pierceall WE; Olaussen KA; Rousseau V; Brambilla E; Sprott KM; Andre F; Pignon JP; Le Chevalier T; Pirker R; Jiang C; Filipits M; Chen Y; Kutok JL; Weaver DT; Ward BE; Soria JC
    Ann Oncol; 2012 Sep; 23(9):2245-2252. PubMed ID: 22269178
    [TBL] [Abstract][Full Text] [Related]  

  • 100. [Clinicopathological and prognostic significance of a panel of tumor biomarkers in lung adenocarcinoma: a tissue microarray study].
    Yang X; Xue L; Guo L; Wen P; Lin D
    Zhongguo Fei Ai Za Zhi; 2014 Mar; 17(3):243-53. PubMed ID: 24667263
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.